Clinical trial
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid…
NCT00253565 · Herbert Hurwitz, Other · Completed
Key facts
| NCT number | NCT00253565 |
|---|---|
| Title | Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies |
| Lead sponsor | Herbert Hurwitz, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | capecitabine, imatinib mesylate |
| Enrollment | 25 |
| Start date | Aug 1, 2003 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2010 |
| First posted | Nov 15, 2005 |
| Last update posted | Apr 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: